B

Bioton SA
WSE:BIO

Watchlist Manager
Bioton SA
WSE:BIO
Watchlist
Price: 2.81 PLN -3.77% Market Closed
Market Cap: 241.3m PLN
Have any thoughts about
Bioton SA?
Write Note

Bioton SA
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Bioton SA
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
B
Bioton SA
WSE:BIO
Total Liabilities & Equity
zł790.4m
CAGR 3-Years
-3%
CAGR 5-Years
-3%
CAGR 10-Years
-9%
M
Mabion SA
WSE:MAB
Total Liabilities & Equity
zł179.3m
CAGR 3-Years
-2%
CAGR 5-Years
11%
CAGR 10-Years
2%
R
Read Gene SA
WSE:RDG
Total Liabilities & Equity
zł11.3m
CAGR 3-Years
-11%
CAGR 5-Years
-6%
CAGR 10-Years
0%
G
Genomed SA
WSE:GEN
Total Liabilities & Equity
zł12.1m
CAGR 3-Years
7%
CAGR 5-Years
5%
CAGR 10-Years
N/A
U
Urteste SA
WSE:URT
Total Liabilities & Equity
zł29.6m
CAGR 3-Years
250%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Synthaverse SA
WSE:SVE
Total Liabilities & Equity
zł293.2m
CAGR 3-Years
38%
CAGR 5-Years
27%
CAGR 10-Years
10%
No Stocks Found

Bioton SA
Glance View

Market Cap
241.3m PLN
Industry
Biotechnology

BIOTON SA engages in the manufacture and production of medicine and pharmaceutical substances. The company is headquartered in Warsaw, Woj. Mazowieckie and currently employs 371 full-time employees. The company went IPO on 2005-03-16. The firm is engaged in research, development and wholesale trade of pharmaceutical and biotechnological products. The firm's portfolio consists of oral hypoglycemic drugs (metformin and glimepride) as well as recombinant human insulin in pharmaceutical substance form and for injections. Additionally, the Company provides advertising services. As of December 31, 2011, the Company formed a capital group and operated through its subsidiaries, including BIOTON TRADE Sp. z o.o., Mindar Holdings Ltd, Germonta Holdings Ltd, Tricel SA, SciGen Ltd and BioPartners Holdings AG, among others. On June 12, 2014, it sold a 50% stake in Copernicus Sp. z o.o.

BIO Intrinsic Value
2.83 PLN
Undervaluation 1%
Intrinsic Value
Price
B

See Also

What is Bioton SA's Total Liabilities & Equity?
Total Liabilities & Equity
790.4m PLN

Based on the financial report for Sep 30, 2024, Bioton SA's Total Liabilities & Equity amounts to 790.4m PLN.

What is Bioton SA's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
-9%

Over the last year, the Total Liabilities & Equity growth was -4%. The average annual Total Liabilities & Equity growth rates for Bioton SA have been -3% over the past three years , -3% over the past five years , and -9% over the past ten years .

Back to Top